Last reviewed · How we verify
NCT07379788
ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling
trial testing Sacubitril/Valsartan 49 MG-51 MG Oral Tablet [ENTRESTO] in Heart Failure in 180 participants. Currently enrolling.
28 February 2026
Quick facts
| Lead sponsor | Rehab Werida |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 180 |
| Start date | 25 December 2025 |
| Primary completion | 28 February 2026 |
| Estimated completion | 1 March 2026 |
| Sites | 1 location across Saudi Arabia |
Drugs / interventions tested
- Sacubitril/Valsartan 49 MG-51 MG Oral Tablet [ENTRESTO] — full drug profile →
- Empagliflozin10Mg Tab — full drug profile →
Conditions studied
- Heart Failure — all drugs for Heart Failure →
Sponsor
Rehab Werida — full company profile →
Who can join
Adults 18 to 80, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aimed to compare the effects of ARNI monotherapy versus combined ARNI and SGLT2 inhibitor therapy on Mitral Remodeling Index (MRIx) and Functional mitral regurgitation (FMR) remodeling in patients with heart failure with reduced ejection fraction (HFrEF).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07379788
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Heart Failure
Currently open trials in the same condition.
- NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
- NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
- NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
- NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
- NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
Other Rehab Werida trials
Trials by the same sponsor.
- NCT05813132 — BeEAM Versus CEM in Lymphoma Patients as a Conditioning Regimen Before Autologous Hematopoietic Cell Transplantation · NA · completed
- NCT05459701 — Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD) · Phase 4 · completed
- NCT05459389 — Early Targeted Antibiotic Therapy in Patients With Sepsis · NA · completed
- NCT05291039 — Infliximab and Adalimumab in Inflammatory Bowel Disease Patients. · NA · completed
- NCT05291338 — Pharmacogenetic Study in Hepatocellular Carcinoma Patients. · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07379788 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rehab Werida
- Last refreshed: 30 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07379788.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing